Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Arthritis & Rheumatology (Hoboken, N.J.)|February 28, 2014
Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritisDésirée van der Heijde, Joachim Sieper, Walter P Maksymowych, et al.
Arthritis Research & Therapy|March 29, 2018
Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trialDésirée van der Heijde, Joachim Sieper, Walter P Maksymowych, et al.
Arthritis Care & Research|September 16, 2020
Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With AdalimumabLaura C Coates, Sonya Abraham, William Tillett, et al.
Annals of the Rheumatic Diseases|July 10, 2012
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Joachim Sieper, Désirée van der Heijde, Maxime Dougados, et al.
Rheumatology (Oxford, England)|April 12, 2020
Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III studyHideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, et al.
Annals of the Rheumatic Diseases|March 12, 2013
Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trialFeng Huang, Jieruo Gu, Ping Zhu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2020
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled TrialRonald van Vollenhoven, Tsutomu Takeuchi, Aileen L Pangan, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trialMark C Genovese, Roy Fleischmann, Bernard Combe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor TherapyJoel M Kremer, Paul Emery, Heidi S Camp, et al.
Modern Rheumatology|November 9, 2020
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY studyTsutomu Takeuchi, Maureen Rischmueller, Ricardo Blanco, et al.
Pageof 5